Clinical Trial Update: Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating expanded treatment protocol of ruxolitinib in polycythemia vera patients resistant or intolerant to hydroxyurea with no alternative tre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Polycythemia Vera | Phase 3 | Status: COMPLETED | Results posted: 2019-04-02